H1 Blog

DECEMBER 18, 2023

How will AI impact clinical trials? Every year, we take a look at annual predictions to help life sciences, pharmaceutical, and healthcare companies understand larger industry trends and dynamics to prepare for the new year. Will FDA legislation improve diversity? What platforms will key opinion leaders adopt?

Trials 64

Trials Clinical Trials FDA Pharmaceutical Companies 64

Conversations in Drug Development Trends

MAY 23, 2024

By: Sarah Bly, Regulatory Science and Innovation and Matt Cooper, Executive Director, Therapeutic Strategy Lead, Oncology The European Union (EU) presents a unique set of regulatory challenges and opportunities for clinical trials in oncology. Increased Transparency : Ensures that information on clinical trials is more accessible.

Trials 52

Trials Clinical Trials Therapies Treatment 52

PPD

APRIL 30, 2024

31, 2022, the EU Clinical Trial Regulation (EU CTR) 536/2014 became applicable, heralding a new era for clinical trials in the European Union (EU). In addition, the constant evolution of EMA and Clinical Trials Coordination Group (CTCG) guidelines requires constant attention.

Clinical Trials 52

Clinical Trials Trials Regulations Pharmaceutical Companies 52

The Pharma Data

JANUARY 12, 2021

a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment, announced today it has launched its SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) with the mission to disrupt and accelerate the clinical trial enrollment process.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Clinical Development Pharmaceutical Companies Drug Development 98

Advarra

JUNE 9, 2022

Optimizing clinical trial access for potential patients is a critical goal for researchers and sponsors. How can we make clinical research more accessible to anyone who wishes to participate? Decentralized clinical trials (DCTs) can meet that need, but they come with some challenges.

Clinical Trials 52

Clinical Trials Trials FDA Pharmaceutical Companies 52

Vial

MAY 22, 2024

Introduction Veeva Systems and Vial CRO ( contract research organization ) represent stakeholders in the clinical research landscape, which play integral roles in the successful execution of clinical trials. Overview of Veeva Systems Veeva Systems Inc.

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

H1 Blog

SEPTEMBER 14, 2023

As pharmaceutical companies turn to CROs (Clinical Research Organizations) for trial design and technology, there are new opportunities emerging with healthcare data intelligence that can help ensure a bright future for the industry and to make trials more effective, efficient and accessible.

Clinical Trials 59

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 59

Conversations in Drug Development Trends

APRIL 15, 2024

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs. The post Reimagining CRO Partnerships: The Emerging Preference for Midsize Organizations appeared first on Worldwide Clinical Trials.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Pharmaceutical Companies 52

Vial

MAY 15, 2024

Vial | Pros and Cons The unprecedented consequences of the COVID-19 pandemic gave rise to the advent of decentralized clinical trials (DCTs), which are studies that use telemedicine and remote or local healthcare professionals to enable participants to join from different locations. billion and now functions as a subsidiary.

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

Vial

FEBRUARY 15, 2024

Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Vial

APRIL 10, 2024

The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. The company reported a revenue of $11,116 million for the first nine months of 2023, marking a 4.2%

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

H1 Blog

JULY 30, 2024

Diversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

PPD

NOVEMBER 18, 2024

For example, a biotech developer creating a new antiviral drug could miss a change in one aspect of a regulatory requirement, only to discover at the end of the process that they must restart a clinical trial or resubmit portions of their data.

Clinical Trials 52

Clinical Trials Regulations Compliance Production 52

Conversations in Drug Development Trends

DECEMBER 7, 2023

Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. Moreover, these delays impact getting potentially lifesaving therapies to patients in need.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Olympian Clinical Research

MAY 6, 2021

Here at Olympian Clinical Research, we’re taking huge strides to change that through our very own ongoing, in-house study for patients with depression. . The post Everything You Need To Know About Our TRAIT Depression Study appeared first on Olympian Clinical Research. What Is The TRAIT Depression Study ?

Clinical Trials 52

Clinical Trials Treatment Clinical Research Trials 52

Vial

APRIL 18, 2024

The urgency for novel therapeutic approaches makes ophthalmology a rapidly growing domain of clinical research. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

The Pharma Data

OCTOBER 19, 2020

We welcome them to our team and I am confident in our collective abilities to execute this large late-stage trial enrolling up to 1,600 patients with sepsis and acute kidney injury.”. a multinational pharmaceutical company, where he was the head of Research & Development and responsible for the R&D strategy (France). (UK);

Trials 40

Trials Small Molecule Cell Biology Clinical Trials 40

The Pharma Data

JANUARY 14, 2021

(NASDAQ: FPRX) today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. The ASCO GI presentation slides are available on the company’s website.

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

JUNE 26, 2021

Together with our research partners, BIG conducts landmark, practice-changing trials that can have a significant impact on the lives of women with breast cancer,” sa id David Cameron , Chair of the BIG Executive Board. Adjuvant therapy helps prevent and delay the progression of disease into the later setting.

Clinical Trials 52

Clinical Trials International Trials Therapies 52

Drug Target Review

AUGUST 3, 2023

Clinical trials are now underway for various genetic subtypes of both rare and common diseases, on the understanding that medications utilising genetic biomarkers have a significantly higher chance of success. There are clinical trials underway for genetic subtypes of rare and common diseases.

DNA 52

DNA Clinical Trials Trials Disease 52

The Pharma Data

JANUARY 6, 2021

With the IND approval, UNION is granted permission to advance oral orismilast into Phase 2b trials in humans with moderate to severe plaque psoriasis to evaluate the safety and efficacy of orismilast. We confidently believe in the benefits of oral orismilast, and the IND approval marks a significant milestone in our clinical development.”

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Broad Institute

OCTOBER 3, 2023

Ten years ago, the institute’s Genomics Platform launched a clinical lab, called the Clinical Research Sequencing Platform (CRSP), to offer high-quality molecular tests that can be used in a clinical setting.

Clinical Trials 52

Clinical Trials Laboratories Science Pharmaceutical Companies 52

PPD

NOVEMBER 21, 2022

The medical communication experts at Thermo Fisher Scientific ’s PPD clinical research business were not satisfied with basic patient satisfaction data to inform our clients’ medical communication strategies. Are patients open to follow-up interactions from pharmaceutical companies?

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Pharmaceuticals Production 52

The Pharma Data

MARCH 26, 2021

Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC. 1 The Phase 3 study showed superior efficacy of ponesimod 20mg on the primary endpoint, annualised relapse rate (ARR), with a rate reduction of 30.5% (p=0.0003) compared with teriflunomide.

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

Molecule Blog

MARCH 17, 2023

The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering 52

Engineering Research Clinical Trials Government 52

The Pharma Data

MARCH 8, 2022

We initiated clinical trials in all regions of the world to generate evidence across multiple geographies and diverse, at-risk populations and forged a strategic partnership with Aspen in Africa and others to manufacture our vaccine globally. Head of Global Public Health, Johnson & Johnson, Cilag GmbH International. “We

Vaccine 40

Vaccine Pharmaceutical Companies Pharmaceuticals Clinical Trials 40

The Pharma Data

OCTOBER 22, 2020

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Clinical Development Pharmaceuticals 40

Agency IQ

FEBRUARY 12, 2024

The consortium is funded by a public-private partnership called the Accelerating Medicines Partnership (AMP) , through which the Foundation for the NIH (FNIH) administers funds provided by industry, government, and nonprofits to scientists working on applicable basic or clinical research to advance gene therapy development for rare diseases.

FDA 40

FDA Therapies Clinical Trials Disease 40

The Pharma Data

APRIL 17, 2021

The collaboration, launched in 2019, has successfully combined MD Anderson’s innovative clinical research infrastructure and the patient-driven drug development capabilities of the Therapeutics Discovery division with Boehringer Ingelheim’s pipeline of innovative cancer medicines and expertise in advancing breakthrough therapies.

Therapies 52

Therapies Drug Development Treatment Clinical Trials 52

The Pharma Data

JANUARY 17, 2021

The service is expected to become operational in 2021 and will be available for clinical research and clinical care — starting with private patients, followed by expansion into the public healthcare system over time. “We This press release features multimedia. View the full release here: [link].

Clinical Trials 40

Clinical Trials FDA Approval Treatment Trials 40

The Pharma Data

DECEMBER 15, 2020

As the world’s first PPAR pan agonist that completed two confirmatory phase III clinical trials, Chiglitazar Sodium has shown significant and long-lasting hypoglycemic effects in a series of clinical studies, as well as other comprehensive effects including significant insulin sensitization and blood lipid regulation.

Pharmaceuticals 40

Pharmaceuticals Clinical Trials Small Molecule Disease 40

The Pharma Data

JANUARY 24, 2021

More information about Sairiyo is available on the company’s website which is located at www.sairiyothera.com. In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties.

FDA 52

FDA Drugs Clinical Development Disease 52

The Pharma Data

SEPTEMBER 1, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. The safety profile observed in the trial was consistent with previous studies of INVEGA SUSTENNA ® and INVEGA TRINZA ® with no new safety signals emerging. About the Clinical Trial. Results found that 92.5

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.

Therapies 52

Therapies Virus Treatment Clinical Trials 52

Agency IQ

OCTOBER 27, 2023

WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025.

FDA 40

FDA Science Regulations Production 40